Evidence map›Paper›PMID 41333448›Full record

ArticleJugan geon-gang gwa jilbyeong2024

[National Surveillance and Response to Possible and Suspected Middle East Respiratory Syndrome Cases in the Republic of Korea, 2022].

Sangeun Lee, Su-Yeon Lee, Sang-Gu Yeo

Abstract readCase ReportsEnglish Abstract
In one paragraph

Article in Jugan geon-gang gwa jilbyeong, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sangeun Lee질병관리청 감염병위기대응국 신종감염병대응과.
Su-Yeon Lee질병관리청 감염병위기대응국 신종감염병대응과.
Sang-Gu Yeo질병관리청 감염병위기대응국 신종감염병대응과.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Middle East Respiratory Syndrome (MERS) is an acute respiratory infection transmitted mainly through camels and individuals infected with the MERS-CoV. It was first reported in Saudi Arabia in 2012 and is predominantly prevalent in the Middle East. By 2022, there were 341 possible cases of MERS in the Republic of Korea. The winter months of January and February contributed to 30.2% (103 cases) of all reports in 2022, followed by a decrease; however, an increase was observed during the second half of the year. This is presumed to be attributed to the simultaneous response policy to coronavirus disease 2019 (COVID-19) and MERS implemented in December 2021, the international easing of COVID-19 prevention measures, an increase in travelers from the Middle East, and seasonal factors. Among the 341 possible MERS cases reported in 2022, 122 suspected MERS cases classified as underwent MERS testing with no confirmed cases. Moreover, to efficiently prevent the influx of MERS, along with COVID-19 prevention measures during the quarantine stage, a simultaneous response policy to COVID-19 and MERS was implemented in December 2021. Suspected MERS cases were transferred to quarantine facilities within the quarantine station for simultaneous testing for COVID-19 and MERS, replacing the previous practice of conducting tests after transfer to hospitals. This convenience appears to have led to the proactive reporting and surveillance of possible MERS symptoms at the quarantine stage. Therefore, we propose further analyses on the convenience of conducting MERS tests at quarantine facilities and their impact on MERS surveillance. This information can be actively utilized in the development of new MERS surveillance systems.

Indexed as

MERS-CoVMiddle East Respiratory SyndromePossible casesSuspected casesThe simultaneous response policy to COVID-19 and Middle East Respiratory Syndrome

Identifiers

PMID41333448
PMCPMC12479709

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.